In This Story
Vivos Therapeutics Inc. (VVOS-3.00%) has filed its Form 10-K filing for the fiscal year ended December 31, 2024.
The filing details Vivos Therapeutics' focus on developing and commercializing diagnostic and treatment modalities for cranial, dentofacial, and postural abnormalities, including obstructive sleep apnea (OSA).
The company reported a net loss of $11.1 million for the year, a decrease from the $13.6 million loss reported in 2023. Revenue increased to $15.0 million from $13.8 million the previous year.
Vivos Therapeutics' new strategic marketing and distribution alliance strategy was highlighted, with the company entering its first alliance with Rebis Health Holdings, LLC, aiming to drive sales of its appliances.
The company continues to focus on expanding its market presence through strategic alliances and potential acquisitions of sleep testing and treatment centers.
Vivos Therapeutics reported cash and cash equivalents of $6.3 million as of December 31, 2024, and acknowledged the need for additional capital to fund operations and meet Nasdaq listing requirements.
The filing also discusses the company's intellectual property portfolio, including patents and trademarks, and ongoing clinical research to support its product offerings.
Vivos Therapeutics outlined its compliance with various regulatory requirements, including FDA approvals for its appliances, and highlighted its efforts to address cybersecurity risks.
The company is subject to several risk factors, including reliance on the commercial viability of its products, potential regulatory changes, and the need for additional capital to continue operations.
Vivos Therapeutics' strategic goals include expanding public awareness of OSA, increasing strategic alliances, and achieving insurance reimbursement for its treatments.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the Vivos Therapeutics Inc. annual 10-K report dated March 31, 2025. To report an error, please email earnings@qz.com.